Find research datasets worth reusing

opennotspecifiedMar 2021View details →

Fig. 7 in Guaiane-type sesquiterpenoids from the roots of Stellera chamaejasme L. and their neuroprotective activities

Fig. 7. Biogenetic pathway of the formation of 1–11.

Fig. 6 in Neuroprotective compounds from the resinous heartwood of Aquilaria sinensis

Fig. 6. Ring-chain tautomerization of compounds 5 and 5a.

Fig. 5 in Neuroprotective compounds from the resinous heartwood of Aquilaria sinensis

Fig. 5. Plausible biogenetic pathways of compounds 2 and 3.

Fig. 3. X in Neuroprotective compounds from the resinous heartwood of Aquilaria sinensis

Fig. 3. X-ray crystallographic structure of 1.

Fig. 4. ECD calculations for compounds 2, 3, 6 in Neuroprotective compounds from the resinous heartwood of Aquilaria sinensis

Fig. 4. ECD calculations for compounds 2, 3, 6, and 7a–7d.

Fig. 1 in Neuroprotective compounds from the resinous heartwood of Aquilaria sinensis

Fig. 1. Structures of compounds 1–21 and 5b.

Fig. 2. Key 2D in Neuroprotective compounds from the resinous heartwood of Aquilaria sinensis

Fig. 2. Key 2D NMR correlations of 1–7 and 5b.

opennotspecifiedSep 2020View details →

Fig. 2 in Isolation, structure elucidation and neuroprotective effects of caffeoylquinic acid derivatives from the roots of Arctium lappa L.

Fig. 2. The key HMBC (1H→13C) correlations of compounds 1–5.

opennotspecifiedSep 2020View details →

Fig. 1 in Isolation, structure elucidation and neuroprotective effects of caffeoylquinic acid derivatives from the roots of Arctium lappa L.

Fig. 1. Chemical structures of compounds 1–5.

opennotspecifiedApr 2023View details →

Fig. 4 in Diversity of sesquiterpenoids from Stellera chamaejasme with neuroprotective effects

Fig. 4. Experimental and calculated ECD spectra (A–D) of 1 4.

Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2

ClinicalTrials.gov study NCT01976936. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation

ClinicalTrials.gov study NCT03982420. IPD Sharing: UNDECIDED. Countries: 2. Publications: 0.

Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries

ClinicalTrials.gov study NCT05674565. IPD Sharing: NO. Countries: 1. Publications: 0.

Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke

ClinicalTrials.gov study NCT07260760. IPD Sharing: Not stated. Countries: 0. Publications: 1.

controlledIPD-YESFeb 2026View details →

Is Cognitive Training Neuroprotective in Early Psychosis?

ClinicalTrials.gov study NCT03049800. IPD Sharing: YES. Countries: 1. Publications: 0.

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

ClinicalTrials.gov study NCT00267007. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Neuroprotection in Acute Ischemic Stroke

ClinicalTrials.gov study NCT03320018. IPD Sharing: NO. Countries: 1. Publications: 0.

Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury

ClinicalTrials.gov study NCT02240589. IPD Sharing: NO. Countries: 1. Publications: 0.

Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain

ClinicalTrials.gov study NCT01553916. IPD Sharing: NO. Countries: 1. Publications: 0.

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

ClinicalTrials.gov study NCT01470027. IPD Sharing: Not stated. Countries: 1. Publications: 0.